Overview

Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy

Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of the study is to determine the safety and efficacy of TNK infusion for the treatment of loculated pleural effusions in patients with known malignancy compared to normal saline infusion.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kaiser Permanente
Collaborator:
Genentech, Inc.
Treatments:
Tenecteplase
Tissue Plasminogen Activator
Criteria
Inclusion Criteria:

- Ability to provide written informed consent and comply with study assessments for the
full duration of the study.

- Age > 18 years

- Adult, non-gravid patients with malignancy and symptomatic loculated pleural effusion
who has undergone percutaneous drainage will be eligible to participate. A loculated
effusion is defined as an effusion whose contents cannot be completely drained at the
time of initial catheter placement as documented by the initial imaging guided
procedure or within 48 hours of catheter placement by chest radiography. Malignant
cells need not be found within the pleural fluid.

Exclusion Criteria:

- Active internal bleeding, involving intracranial and retroperitoneal sites, or the
gastrointestinal, genitourinary, or respiratory tracts

- History of stroke within 3 months

- Intracranial neoplasm, arteriovenous malformation, or aneurysm.

- Uncorrectable bleeding diathesis (INR > 1.5 despite therapy)

- Recent intracranial or intraspinal surgery or trauma

- Pregnancy (positive pregnancy test)

- Severe uncontrolled hypertension

- Documented empyema

- Any other condition that the investigator believes would pose a significant hazard to
the subject if the investigational therapy were initiated

- Participation in another simultaneous medical investigation or trial

- Participation in another clinical investigation within previous 30 days of catheter
placement

- Prior enrollment in the study

- Known allergy to TNK or any of its components